2018
Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study
Visvanathan K, Shaw P, May BJ, Bahadirli-Talbot A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM. Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study. Cancer Prevention Research 2018, 11: canprevres.0009.2018. PMID: 30232083, PMCID: PMC6760670, DOI: 10.1158/1940-6207.capr-18-0009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCystadenocarcinoma, SerousDisease ProgressionFallopian Tube NeoplasmsFallopian TubesFemaleHumansMedical History TakingMiddle AgedOvarian NeoplasmsOvaryPrecancerous ConditionsPrevalencePrognosisProspective StudiesRetrospective StudiesSalpingo-oophorectomyConceptsSerous tubal intraepithelial lesionsHigh-grade serous ovarian carcinomaSerous tubal intraepithelial carcinomaP53 signatureRisk/protective factorsProtective factorsMultiple lesionsFallopian tubePrognosis of womenHigh-risk womenTubal intraepithelial carcinomaTubal intraepithelial lesionsSerous ovarian carcinomaPutative precursor lesionsYears of ageIntraepithelial lesionsIntraepithelial carcinomaMulticenter studyInvasive cancerOvarian carcinomaDisease progressionPrecursor lesionsEpidemiologic dataCombined prevalenceTubal lesions
2017
History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva AN, Consortium JL, Freudenheim KH, Eng RA, Cannioto G, Friel JB, Szender B, Segal K, Odunsi P, Mayor B, Diergaarde E, Zsiros LE, Kelemen M, Köbel H, Steed A, deFazio SJ, Group PA, Jordan MW, Fasching HA, Beckmann MA, Risch JA, Rossing J, Doherty MT, Chang-Claude T, Goodman R, Dörk F, Edwards RB, Modugno K, Ness M, Matsuo BY, Mizuno EL, Karlan SK, Goode E, Kjær JM, Høgdall KL, Schildkraut DW, Terry EV, Cramer LE, Bandera LA, Paddock LFAG, Kiemeney R, Massuger H, Sutphen A, Anton-Culver U, Ziogas SA, Menon SJ, Gayther A, Ramus CL, Gentry-Maharaj AH, Pearce J, Wu A, Kupryjanczyk PM, Jensen KB, Webb P, Moysich K. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1470-1473. PMID: 28864456, PMCID: PMC5649363, DOI: 10.1158/1055-9965.epi-17-0367.Peer-Reviewed Original ResearchConceptsProgression-free survivalHistory of endometriosisStage of diseaseOvarian cancer patientsOvarian cancer outcomeCancer outcomesCancer patientsCox proportional hazards regression modelProportional hazards regression modelsHazards regression modelsInvasive ovarian carcinomasOvarian cancer prognosisOvarian Cancer Association ConsortiumPooled HRsConcurrent comorbiditiesHistologic subtypeOvarian carcinomaChronic diseasesOvarian cancerWeight statusNeurologic diseaseCancer prognosisComorbiditiesTreatment efficacyNeurological diseases
2016
Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk
Lee A, Ness R, Roman L, Terry K, Schildkraut J, Chang-Claude J, Doherty J, Menon U, Cramer D, Gayther S, Risch H, Gentry-Maharaj A, Goodman M, Modugno F, Eilber U, Moysich K, Berchuck A, Rossing M, Jensen A, Wicklund K, Cushing-Haugen K, Hogdall E, Rudolph A, Thompson P, Wilkens L, Kjaer S, Carney M, Stram D, Ramus S, Wu A, Pike M, Pearce C. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrical & Gynecological Survey 2016, 71: 470-471. DOI: 10.1097/01.ogx.0000489579.62561.b8.Peer-Reviewed Original ResearchAssociation Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk
Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, Doherty JA, Menon U, Cramer DW, Gayther SA, Risch H, Gentry-Maharaj A, Goodman MT, Modugno F, Eilber U, Moysich KB, Berchuck A, Rossing MA, Jensen A, Wicklund KG, Cushing-Haugen KL, Hogdall E, Rudolph A, Thompson PJ, Wilkens LR, Kjaer SK, Carney ME, Stram DO, Ramus SJ, Wu AH, Pike MC, Pearce CL. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrics And Gynecology 2016, 127: 828-836. PMID: 27054934, PMCID: PMC4892111, DOI: 10.1097/aog.0000000000001387.Peer-Reviewed Original ResearchConceptsEndometrioid ovarian carcinomaTherapy useOvarian carcinomaPostmenopausal estrogenControl groupPopulation-based case-control studyCase-control studyOvarian carcinoma histotypesOvarian carcinoma riskConditional logistic regressionOvarian Cancer Association ConsortiumSerous ovarian carcinomaDuration of useTiming of useTherapy usersMenopausal estrogensPooled analysisRisk factorsSelf-reported questionnaire dataCarcinoma riskCarcinomaEstrogenRecent usersLogistic regressionHistotype
2015
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium
Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Fasching P, Beckmann M, Lambrechts D, Vergote I, Van Nieuwenhuysen E, Lambrechts S, Risch H, Rossing M, Doherty J, Wicklund K, Chang-Claude J, Goodman M, Ness R, Moysich K, Heitz F, du Bois A, Harter P, Schwaab I, Matsuo K, Hosono S, Goode E, Vierkant R, Larson M, Fridley B, Høgdall C, Schildkraut J, Weber R, Cramer D, Terry K, Bandera E, Paddock L, Rodriguez-Rodriguez L, Wentzensen N, Yang H, Brinton L, Lissowska J, Høgdall E, Lundvall L, Whittemore A, McGuire V, Sieh W, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Pearce C, Wu A, Webb P. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal Of Cancer 2015, 113: 817-826. PMID: 26151456, PMCID: PMC4559823, DOI: 10.1038/bjc.2015.245.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexOvarian cancer-specific survivalCancer-specific survivalOvarian cancerHazard ratioHistologic subtypeOverall survivalHigh-grade serous cancerHigher Body Mass IndexInvasive ovarian cancerPooled hazard ratioDifferent histologic subtypesOvarian Cancer Association ConsortiumMajority of womenRandom-effects modelAdverse survivalPooled HRsSerous cancerEndometrioid subtypeMass indexOvarian carcinomaObservational studyModest associationCancer
2013
Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium
Kelemen LE, Bandera EV, Terry KL, Rossing MA, Brinton LA, Doherty JA, Ness RB, Kjær S, Chang-Claude J, Köbel M, Lurie G, Thompson PJ, Carney ME, Moysich K, Edwards R, Bunker C, Jensen A, Høgdall E, Cramer DW, Vitonis AF, Olson SH, King M, Chandran U, Lissowska J, Garcia-Closas M, Yang H, Webb PM, Schildkraut JM, Goodman MT, Risch HA, , on behalf of the Australian Ovarian Cancer Study Group and Australian Cancer Study (Ovarian Cancer), and on behalf of the Ovarian Cancer Association Consortium. Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer 2013, 13: 28. PMID: 23339562, PMCID: PMC3568733, DOI: 10.1186/1471-2407-13-28.Peer-Reviewed Original ResearchConceptsOvarian carcinomaOvarian Cancer Association ConsortiumHistologic typeAlcohol intakeBorderline tumorsOdds ratioClear cell ovarian carcinomaOz/dModerate alcohol drinkingTumor histologic typeSpecific histologic typesCase-control studyConfidence intervalsRecent alcohol intakeRecent alcohol consumptionAverage daily intakeModifiable causesMucinous histologySmoking statusAlcohol drinkingStatistical heterogeneityOC casesRisk associationAlcohol consumptionDeadly cancer
2002
Histopathologic Features of Genetically Determined Ovarian Cancer
Shaw P, McLaughlin J, Zweemer R, Narod S, Risch H, Verheijen R, Ryan A, Menko F, Kenemans P, Jacobs I. Histopathologic Features of Genetically Determined Ovarian Cancer. International Journal Of Gynecological Pathology 2002, 21: 407-411. PMID: 12352190, DOI: 10.1097/00004347-200210000-00011.Peer-Reviewed Original ResearchConceptsInvasive serous carcinomasOvarian carcinomaSilverberg gradeGermline mutationsHistologic typeSerous carcinomaNuclear gradeGOG grade 3High histologic gradeBRCA1/BRCA2Serous histologyGynecologic pathologistsHistologic featuresHistopathologic featuresBRCA carriersHistologic gradeBRCA mutationsOvarian cancerArchitectural gradeBRCA2 mutationsGrade 3Germline BRCA1CarcinomaMutation statusControl group
1997
Perineal talc exposure and risk of ovarian carcinoma
Chang S, Risch H. Perineal talc exposure and risk of ovarian carcinoma. Cancer 1997, 79: 2396-2401. PMID: 9191529, DOI: 10.1002/(sici)1097-0142(19970615)79:12<2396::aid-cncr15>3.0.co;2-m.Peer-Reviewed Original ResearchConceptsOvarian carcinomaTalc exposureFrequency of exposureUnconditional logistic regression methodsTalcum powder useInvasive ovarian carcinomasBorderline significant associationPerineal talc exposureBorderline carcinomaMenstrual historyInvasive carcinomaCarcinoma typesEpidemiologic studiesEpidemiologic investigationsCarcinomaSignificant associationPowder useHistologic sectionsLogistic regression methodRole of talcSignificant riskFurther studiesOnly riskRiskPerineum